NCT04338074 (TCOutpatient) is a Phase 2 clinical trial of Tranexamic acid tablets in COVID-19, sponsored by University of Alabama at Birmingham.

Who is sponsoring NCT04338074?

NCT04338074 is sponsored by University of Alabama at Birmingham.

What drugs are being tested in NCT04338074?

Interventions in NCT04338074: Tranexamic acid tablets, Placebo oral tablet.

Is NCT04338074 still recruiting?

NCT04338074 is currently terminated. Last updated 13 May 2021.

Are results published for NCT04338074?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-05-13 · How we verify

NCT04338074: TCOutpatient

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TXA and Corona Virus 2019 (COVID19) in Outpatients

Terminated Phase 2 Results posted Last updated 13 May 2021

What this trial tests

Phase 2 trial testing Tranexamic acid tablets in COVID-19 in 5 participants. Terminated before completion.

Timeline

1 June 2020

Primary endpoint
21 April 2021

21 April 2021

Quick facts

Lead sponsor	University of Alabama at Birmingham
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	5
Start date	1 June 2020
Primary completion	21 April 2021
Estimated completion	21 April 2021
Sites	1 location across United States

Drugs / interventions tested

Tranexamic acid tablets — full drug profile →
Placebo oral tablet — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

University of Alabama at Birmingham

Who can join

19 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Hospitalization Primary · Randomization to 7 days after randomization

Participant admission to hospital for COVID-19 treatment

Group	Value	95% CI
Tranexamic Acid Treatment	0
Placebo Treatment	0

Sponsor's own description

A controlled trial of the drug tranexamic acid (TXA) in outpatients who were recently diagnosed with COVID-19. It is hypothesized that TXA will reduce the infectivity and virulence of the virus.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic.
Driggin E, Madhavan MV, Bikdeli B, Chuich T, et al · · 2020 · cited 1272× · PMID 32201335 · DOI 10.1016/j.jacc.2020.03.031
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2020 · cited 105× · PMID 32717568 · DOI 10.1016/j.drup.2020.100719
Fibrinolysis and COVID-19: A plasmin paradox.
Medcalf RL, Keragala CB, Myles PS. · · 2020 · cited 78× · PMID 32543119 · DOI 10.1111/jth.14960
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
Hu S, Jiang S, Qi X, Bai R, et al · · 2022 · cited 68× · PMID 34762760 · DOI 10.1002/ddr.21895
Thromboembolic events and Covid-19.
Ribes A, Vardon-Bounes F, Mémier V, Poette M, et al · · 2020 · cited 55× · PMID 32773098 · DOI 10.1016/j.jbior.2020.100735
Fibrinolysis Shutdown in COVID-19: Clinical Manifestations, Molecular Mechanisms, and Therapeutic Implications.
Meizoso JP, Moore HB, Moore EE. · · 2021 · cited 48× · PMID 33766727 · DOI 10.1016/j.jamcollsurg.2021.02.019
Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials.
Al-Horani RA, Kar S, Aliter KF. · · 2020 · cited 35× · PMID 32718020 · DOI 10.3390/ijms21155224

Verify or expand the search:

Other trials of Tranexamic acid tablets

Trials testing the same drug.

NCT04233749 — The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans · Phase 2 · recruiting
NCT04187014 — Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss After Total Hip Replacement · Phase 2 · completed
NCT04055194 — Antenatal Tranexamic Acid in Women With Symptomatic Placenta Previa · Phase 2, PHASE3 · unknown

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other University of Alabama at Birmingham trials

Trials by the same sponsor.

NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04338074 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
Last refreshed: 13 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04338074.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing